Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Vorolanib Tablets With Rifampicin or Itraconazole in Healthy Participants
NCT07809789Phase 1Recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorolanib in cancer (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Maximum plasma concentration at 120 hours, Area under the plasma concentration-time curve from time 0 to the last measurable concentration at 120 hours and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
vorolanib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07809789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809789.